Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Empowered by our Human Leukocyte Antigen (HLA) expertise and advanced high-resolution sequencing platforms, Creative Biolabs is fully competent and dedicated to HLA typing service to facilitate your HLA research and associated TCR research. We are committed to ultra-high-resolution HLA typing in a highly efficient way.
The Human Leukocyte Antigen (HLA) system is a series of major histocompatibility complex (MHC) proteins in humans. They are cell-surface proteins that play important roles in the immune system in humans. Studies have demonstrated that HLA is critical for disease defense, protection from cancers, organ transplant rejections. In addition, HLA can be potential biomarkers of susceptibility to some diseases or drug adverse reactions. 11 HLA types of major MHC complexes are exhibited in Fig.1. HLA is highly polymorphic, thus investigating the polymorphism is necessary and challenging.
Fig.1 HLA type of major MHC molecules.
With traditional genotyping approaches, the highly polymorphic feature makes HLA typing be challenging. Creative Biolabs has developed a dedicated NGS-based HLA typing service to meet your program requirements. We are committed to precise and high-resolution results for HLA typing service. Our HLA typing service enables fast, reliable, and most cost-effective way to fulfill your needs. Our scientists and technicians are experienced in every step with high dedication to ensuring accurate outcomes. Here is a brief workflow for your reference, including sample preparation, library construction, NGS sequencing, and data analysis, etc.
Fig.2 HLA typing workflow.
As a reliable partner in the immunology, Creative Biolabs aspires to become the best solution provider of our clients. We are committed to the HLA typing service and dedicated to reducing the overall project development timeline for our clients. Please don't hesitate to contact us to learn more.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
